enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Esketamine - Wikipedia

    en.wikipedia.org/wiki/Esketamine

    Esketamine, sold under the brand names Spravato (for depression) and Ketanest (for anesthesia) among others, [10] [12] is the S(+) enantiomer of ketamine. [5] [13] It is a dissociative hallucinogen drug used as a general anesthetic and as an antidepressant for treatment of depression.

  3. FDA-approved nasal spray for severe depression can lead to ...

    www.aol.com/fda-approved-nasal-spray-severe...

    The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.

  4. Nasal esketamine works better than alternative for treatment ...

    www.aol.com/news/nasal-esketamine-works-better...

    At week 32, 49.1% of patients in the esketamine group and 32.9% of the patients in the quetiapine group were in remission. The study had limitations. It compared nasal esketamine to only one other ...

  5. Ketamine in society and culture - Wikipedia

    en.wikipedia.org/wiki/Ketamine_in_society_and...

    After the publication of the NIH-run antidepressant clinical trial, clinics began opening in which the intravenous ketamine is given for depression. [5] [6] This practice is an off label use of IV ketamine in the United States, though the intranasal version of esketamine has been approved by the FDA for treatment of depression [5] [7] In 2015 there were about 60 such clinics in the US; the ...

  6. Nose spray to treat depression? FDA approves first-of-its ...

    www.aol.com/news/nose-spray-treat-depression-fda...

    The main ingredient for the spray is esketamine hydrochloride, which is the “chemical cousin” of ketamine. Ketamine has been used by clinics across the U.S. to treat depression, anxiety and ...

  7. Treatment-resistant depression - Wikipedia

    en.wikipedia.org/wiki/Treatment-resistant_depression

    Spravato, a nasal spray form of esketamine, was approved by the FDA in 2019 for use in treatment-resistant depression when combined with an oral antidepressant. [15] [16] Some low to moderate quality evidence points to success in the short term (8–12 weeks) using mianserin to augment antidepressant medications. Simply switching to mianserin ...

  8. NMDA receptor antagonist - Wikipedia

    en.wikipedia.org/wiki/NMDA_receptor_antagonist

    NMDA receptor antagonists induce a state called dissociative anesthesia, marked by catalepsy, amnesia, and analgesia. [1] Ketamine is a favored anesthetic for emergency patients with unknown medical history and in the treatment of burn victims because it depresses breathing and circulation less than other anesthetics.

  9. FDA Panel Nod for J&J's Esketamine Is Good News for ... - AOL

    www.aol.com/news/fda-panel-nod-j-js-170323319.html

    Esketamine is the molecular mirror image of the sedative ketamine, often prescribed off-label for severe cases of depression involving the risk of suicide. FDA Panel Nod for J&J's Esketamine Is ...